1. <video id="oovo1"></video>
          <b id="oovo1"><p id="oovo1"></p></b><source id="oovo1"></source>
            <source id="oovo1"></source>
          1. 中文 英文
             

            產品中心

             降糖藥物
             抗腫瘤藥
             心血管藥
             其他

            聯系方式

            總機:021-64556180
            傳真:021-021-69018966*808
            地址:上海市閔行區曲吳路589號夢谷6號樓4樓
            郵編:200241
            聯系人:林女士
            Q Q:2377734184

            郵箱:service@caerulumpharma.com
            網址:www.tmesiep.cn

            研發動態

            Zybrestat/Avastin組合療法卵巢癌II期研究達主要終點
            2014-03-16         

             

            Zybrestat/Avastin組合療法卵巢癌II期研究達主要終點

            2014年3月12日訊 /生物谷BIOON/ --Oxigene公司3月11日公布了一項隨機II期GOG186I研究的積極數據。該項研究調查了Zybrestat(fosbretabulin,CA4P)與羅氏(Roche)暢銷藥物安維?。ˋvastin,通用名:bevacizumab,貝伐單抗)組合療法用于復發性卵巢癌的治療。數據表明,與Avastin單藥治療組相比,Zybrestat+Avastin聯合治療組疾病無進展生存期(PFS)顯著延長(p<0.05),達到了研究的主要終點。消息發布后,Oxigene公司股價在盤后交易中飆升1倍多。

            GOG186I研究的詳細PFS數據將公布于未來的醫學會議。該公司稱,將對GOG186I研究的患者隨訪,以便確認Zybrestat+Avastin組合療法是否能改善總生存期(OS)。

            該項研究驗證了具有互補機制的血管破壞劑Zybrestat和抗血管生成劑(如Avastin)在卵巢癌中的治療潛力。Zybrestat和Avastin均能夠抑制腫瘤生長所需的血液供應和氧氣供應,但作用機制不同。鑒于當前復發性卵巢癌群體對新治療方案的重大需求,這一有前途的組合療法,值得開展III期進一步評價。

            目前,在美國,Avastin還未獲批用于卵巢癌的治療,但在其他一些國家已獲批用于卵巢癌適應癥。

            GOG186I研究由非營利組織婦科腫瘤學組(GOG)開展,由美國國家癌癥研究所(NCI)癌癥療法評估項目(CTEP)資助,這是首個將一種抗血管生成治療藥物與一種血管破壞劑進行聯合用藥的隨機研究,而且沒用使用任何細胞毒性藥物化療。

            關于Zybrestat

            Zybrestat(fosbretabulin tromethamine)是由Oxigene公司開發的名為血管破壞劑(vascular disrupting agents)的新一類小分子藥物,通過與血管內皮細胞的細胞骨架蛋白相互作用,Zybrestat選擇性作用于腫瘤中的血管,并破壞這些血管,從而使腫瘤失去氧氣供給而凋亡。該藥已表現出對未分化甲狀腺癌、卵巢癌及其他各種實體瘤的治療潛力。

            此前,歐洲藥品管理局(EMA)于2013年授予Zybrestat治療卵巢癌的孤兒藥地位。(生物谷Bioon.com)

            英文原文:OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer

            Trial Achieves Primary Efficacy Endpoint of a Statistically Significant Increase in Progression-Free Survival

            SOUTH SAN FRANCISCO -- OXiGENE, Inc.OXGN +136.78% , a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less than 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.

            The Phase 2 study is being conducted by the GOG under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). It is the first and currently only randomized trial to test an antiangiogenic therapeutic agent combined with a vascular disrupting agent, without including any cytotoxic chemotherapy.

            "These findings validate both the novel approach and the complementary mechanisms of combining the vascular disrupting agent fosbretabulin and an antiangiogenic agent like bevacizumab in patients with ovarian cancer," said Bradley J. Monk, M.D., FACS, FACOG, principal investigator for the trial, and professor and director, Division of Gynecologic Oncology and Department of Obstetrics and Gynecology at the University of Arizona Cancer Center. "This promising combination warrants further evaluation particularly given the significant need for new treatment options in relapsed ovarian cancer."

            As previously reported, the GOG protocol 186I enrolled 107 patients with platinum-sensitive and -resistant recurrent ovarian cancer at 67 clinical sites in the U.S. Patients were randomized 1:1 into one of two treatment arms: one arm received Avastin, and the second arm received Avastin plus ZYBRESTAT. Both therapies were administered intravenously every three weeks and patients were treated until disease progression or until adverse effects prohibited further therapy.

            Secondary endpoints in the study include safety, objective response rate (measured according to RECIST criteria) and overall survival. Patients receiving the combination of ZYBRESTAT and Avastin achieved a higher objective response rate, which was not statistically significant. All patients will continue to be followed for overall survival. Consistent with prior clinical experience with ZYBRESTAT, patients in the combination arm experienced a higher incidence of hypertension compared to the control arm. All cases of hypertension were managed with antihypertensive treatments, as specified in the study protocol. It is expected that the full study results will be submitted for presentation at a future scientific meeting.

            For this study, ZYBRESTAT is provided to CTEP under a Cooperative Research and Development Agreement (CRADA) with OXiGENE and bevacizumab is being provided as an investigational agent under a CRADA with Genentech. Bevacizumab is not approved to treat women with ovarian cancer in the U.S.; however, it is approved in other countries for treatment of ovarian cancer.

            "We are very excited about these positive results and greatly appreciate all the patients who enrolled in this study and the support, resources and commitment of GOG and CTEP to conduct this important program," said Peter Langecker, M.D., Ph.D., chief executive officer of OXiGENE. "ZYBRESTAT is the first vascular disrupting agent to show a statistically significant progression-free survival benefit, and we are evaluating next steps to advance this combination to patients in need."

            About ZYBRESTAT

            ZYBRESTAT (fosbretabulin tromethamine/combretastatin-A4 phosphate / CA4P) is OXiGENE's lead vascular disrupting agent (VDA) product candidate, and is currently being evaluated as a treatment for solid tumors. ZYBRESTAT exerts its antitumor effects through the validated therapeutic mechanism of tumor blood supply deprivation. By selectively affecting and disabling tumor vasculature, ZYBRESTAT reduces the blood supply necessary for tumor growth and survival. The resulting oxygen starvation and build-up of tumor metabolic by-products causes the cancer cells within the central core of the tumor to die.

            About the Gynecologic Oncology Group

            The Gynecologic Oncology Group (GOG) is a not-for-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. The GOG is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. The GOG is one of the National Cancer Institute's funded cooperative groups. The GOG is the only group that focuses its research on women with pelvic malignancies, such as cancer of the ovary, uterus, and cervix. The GOG is multi-disciplinary in its approach to clinical trials, and includes gynecologic oncologists, medical oncologists, pathologists, radiation oncologists, nurses, statisticians, basic scientists, quality of life experts, data managers, and administrative personnel.

            About OXiGENE

            OXiGENE is a biopharmaceutical company developing novel therapeutics to treat cancer. The Company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression. The Company's lead clinical product candidate, ZYBRESTAT, is in development for solid tumors. OXi4503, its second-generation product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

             

            關鍵詞:Oxigene,Zybrestat,Avastin,卵巢癌

            信息來源:生物谷

             


            總機:021-64556180 傳真:021-021-69018966*808 網址:www.tmesiep.cn 郵箱:service@caerulumpharma.com
             上??β端{科技有限公司 版權所有 © 2014 技術支持 華夏化工網 后臺管理 企業郵箱

            滬公網安備 31011202007132號

            国产亚洲欧美在线人成|亚洲国产成人无码网|国产在线自在拍91精品|亚洲国产精品无码
                1. <video id="oovo1"></video>
                  <b id="oovo1"><p id="oovo1"></p></b><source id="oovo1"></source>
                    <source id="oovo1"></source>